Biology Reference
In-Depth Information
[58] Pihusch M, Pihusch R, Fraunberger P, et al. Evaluation of C-reactive protein, interleu-
kin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J
Haematol 2006;76:93-101.
[59] Uguccioni M, Meliconi R, Nesci S, et al. Elevated interleukin-8 serum concentrations in
beta-thalassemia and graft-versus-host disease. Blood 1993;81:2252-6.
[60] Mohty M, Blaise D, Faucher C, et al. Inflammatory cytokines and acute graft-versus-host
disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood
2005;106:4407-11.
[61] Hori T, Naishiro Y, Sohma H, et al. CCL8 is a potential molecular candidate for the diag-
nosis of graft-versus-host disease. Blood 2008;111:4403-12.
[62] Piper KP, Horlock C, Curnow SJ, et al. CXCL10-CXCR3 interactions play an important
role in the pathogenesis of acute graft-versus-host disease in the skin following allogene-
ic stem-cell transplantation. Blood 2007;110:3827-32.
[63] Okamoto T, Takatsuka H, Fujimori Y, Wada H, Iwasaki T, Kakishita E. Increased hepato-
cyte growth factor in serum in acute graft-versus-host disease. Bone Marrow Transplant
2001;28:197-200.
[64] Luft T, Conzelmann M, Benner A, et al. Serum cytokeratin-18 fragments as quantitative
markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood
2007;110:4535-42.
[65] Kuroiwa T, Kakishita E, Hamano T, et al. Hepatocyte growth factor ameliorates
acute graft-versus-host disease and promotes hematopoietic function. J Clin Invest
2001;107:1365-73.
[66] Reddy P, Sun Y, Toubai T, et al. Histone deacetylase inhibition modulates indoleamine
2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host
disease in mice. J Clin Invest 2008;118:2562-73.
[67] Landfried K, Zhu W, Waldhier MC, et al. Tryptophan catabolism is associated with acute
GVHD after human allogeneic stem cell transplantation and indicates activation of
indoleamine 2,3-dioxygenase. Blood 2011;118:6971-4.
[68] Luft T, Dietrich S, Falk C, et al. Steroid-refractory GVHD: T-cell attack within a vulnerable
endothelial system. Blood 2011;118:1685-92.
[69] Rezvani AR, Storer BE, Storb RF, et al. Decreased serum albumin as a biomarker for
severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic
cell transplantation. Biol Blood Marrow Transplant 2011;17:1594-601.
[70] Weissinger EM, Schiffer E, Hertenstein B, et al. Proteomic patterns predict acute graft-
versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood
2007;109:5511-9.
[71] Harris AC, Ferrara JL, Braun TM, et al. Plasma biomarkers of lower gastrointestinal and
liver acute GVHD.. Blood 2012;119:2960-3.
[72] Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus
development project on criteria for clinical trials in chronic graft-versus-host dis-
ease. I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant
2005;11:945-56.
[73] Socie G, Ritz J, Martin PJ. Current challenges in chronic graft-versus-host disease. Biol
Blood Marrow Transplant 2010;16:S146-51.
[74] Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host dis-
ease after HLA-identical sibling bone marrow transplantation. Blood 1990;75:2459-64.
[75] Fraser CJ, Bhatia S, Ness K, et al. Impact of chronic graft-versus-host disease on the
health status of hematopoietic cell transplantation survivors: a report from the Bone
Marrow Transplant Survivor Study. Blood 2006;108:2867-73.
[76] Schultz KR, Miklos DB, Fowler D, et al. Toward biomarkers for chronic graft-versus-host
disease: National Institutes of Health consensus development project on criteria for
clinical trials in chronic graft-versus-host disease. III. Biomarker Working Group Report.
Biol Blood Marrow Transplant 2006;12:126-37.
[77] Pulanic D, Lozier JN, Pavletic SZ. Thrombocytopenia and hemostatic disorders in
chronic graft versus host disease. Bone Marrow Transplant 2009;44:393-403.
[78] Jacobsohn DA, Schechter T, Seshadri R, Thormann K, Duerst R, Kletzel M. Eosinophilia
correlates with the presence or development of chronic graft-versus-host disease in
children. Transplantation 2004;77:1096-100.
[79] Fujii H, Cuvelier G, She K, et al. Biomarkers in newly diagnosed pediatric-extensive
chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood
2008;111:3276-85.
[80] Liem LM, Fibbe WE, van Houwelingen HC, Goulmy E. Serum transforming growth
factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts
and chronic graft-versus-host disease. Transplantation 1999;67:59-65.
[81] Sarantopoulos S, Stevenson KE, Kim HT, et al. High levels of B-cell activating factor
in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007;13:
6107-14.
477
Search WWH ::
Custom Search